Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

nd involve risks and uncertainties as of the date of this release, including without limitation InterMune's expectation regarding its anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in various European countries; the estimated size of the patient population in Canada suffering from IPF and InterMune's expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof; InterMune's expectation regarding the results of the ASCEND study and the prospects of success thereof and meeting the goal of bringing Esbriet to IPF patients in the United States;  InterMune's expectation in building its Esbriet franchise in North America; InterMune's intent to repurchase the remaining $18.4 million of the outstanding 2015 notes; and InterMune's projected revenue from sales of Esbriet and operating expenses for 2013.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 29, 2012 (the "Form 10-K"), most recent quarterly report on Form 10-Q filed with the SEC on November 9, 2012 (the "Form 10-Q"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the risks related to the uncertain, lengthy and expensive clinical development process for the company's produc
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
2. InterMune to Present at J. P. Morgan Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune To Present At JMP Securities Healthcare Conference
5. InterMune To Release Third Quarter Financial Results On November 7
6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... ... August 05, 2015 , ... ... announces the launch of an updated corporate identity, including new company name, logo ... (MTI) in 2009. The company moved into a new, joint facility in 2014 ...
(Date:8/4/2015)... , Aug. 4, 2015 Trigemina, Inc., a ... non-narcotic, nasally delivered, analgesic drug products, announced today that ... the position of chief medical officer. Dr. Kori brings ... much of which has been focused in the neuroscience ... add Dr. Kori to our clinical team given his ...
(Date:8/4/2015)... ... , ... On August 4, 2015, the White House will host a Demo ... United States to talk about their experiences with innovation and present their big ideas. ... the attendees. , One of the day’s aims is to grow the innovation economy, ...
(Date:8/3/2015)... 2015 At the 11th hour, ... waved the shortfall of Jude Liversage,s campaign ... the first time.      (Photo: http://photos.prnewswire.com/prnh/20150803/254228 ... ) The Selective Dorsal Rhizotomy (SDR) procedure ... carry out his wish to kick a ball around ...
Breaking Biology Technology:MTI-GlobalStem Announces Updated Company Identity and Website 2MTI-GlobalStem Announces Updated Company Identity and Website 3Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3
... in three short months! The major stock indices looked pretty ... up steam in the second quarter with the Dow Jones ... eight percent growth for the first half. Not far behind was ... the first quarter and 7% growth for the half year. , ...
... controversy over its proposed overhaul of the state's healthcare system ... pare back additional funding for the Act 255 tax credit ... Joint Committee on Finance. , ,The caucus voted to delete ... investment and early-stage seed investment tax credits. , ,According ...
... CEOs caught up in the scandals of WorldCom, ENRON, and TYCO ... Grigsby . The people on this video make them look like ... for people trying to make a living to support their families. ... in the last couple of years that have not been able ...
Cached Biology Technology:Midwest life science stocks kept sizzling in Q2 2Midwest life science stocks kept sizzling in Q2 3Midwest life science stocks kept sizzling in Q2 4Midwest life science stocks kept sizzling in Q2 5Midwest life science stocks kept sizzling in Q2 6Senate Democrats strip additional Act 255 funding from budget 2A disgusting video: U.S. companies sell out Americans 2A disgusting video: U.S. companies sell out Americans 3A disgusting video: U.S. companies sell out Americans 4
(Date:7/21/2015)... 2015 Today, ZTE announced its Android smartphone ... as expected revenues in 2015 that relate to sales of FPC1025 ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO ... manufacturer in China and we are proud ... 5 for Axon , its first ...
(Date:7/13/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... method to make payments.  With this patent, NXT-ID ... its groundbreaking voice-direct payment patent application, with behavior-directed ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... a paper published today in Diabetologia , a team at ... the enzyme AMP kinase (AMPK) as key to the molecular mechanism ... spina bifida and some heart defects among babies born to women ... type 1 or type 2 -- work vigilantly to control their ...
... (PHB) is a thermoplastic polyester which occurs naturally in ... megaterium . Even though PHB is biodegradable and is ... traditionally too expensive to produce to replace petroleum-based plastics. ... Microbial Cell Factories describes an alternative method ...
... time, researchers have found a way to inject a precise ... living cell without a needle. The technique uses electricity ... and into a cell in a fraction of a second. ... University describe the technique in the online edition of the ...
Cached Biology News:Joslin study finds clue to birth defects in babies of mothers with diabetes 2Researchers do precise gene therapy without a needle 2Researchers do precise gene therapy without a needle 3
... Designed specifically for ... mammalian cells. Low toxicity reagent ... a wide range of cell ... greater than 95% of target ...
... Definitive Performance The TSQ ... quantitation excellence in bioanalytical and environmental analysis. ... source ESI and APCI probes, a titanium ... for increased robustness and sensitivity. Its ...
... This stain is used to distinguish ... the Artisan™ Staining System. The Trichrome stain ... and smooth muscle and to identify an ... Masson's Trichrome stain, muscle is stained red, ...
... w/ OutputCumulates a score of movement counts, similar ... it.can track up to 6 subjects at once, ... triggered. Can outpt a sync pulse to ... Can use animal location and timing information to ...
Biology Products: